Frates James M's Form 4 filing
Amylyx Pharmaceuticals, Inc.AMLX · filed Nov 12, 2026
- Accession no.
- 0001193125-26-458247
- Filed
- Nov 12, 2026, 4:00 PM ET
- Trade date
- Nov 9-10, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.21M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Frates James MCIK 0001235598 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $6.88 | +$137,600 | 253,625 | Direct | |
| Nov 9, 2026 | Common Stock | SSaleDisposed | −7,700 | $29.39F2 | −$226,292.99 | 245,925 | Direct | |
| Nov 9, 2026 | Common Stock | SSaleDisposed | −12,300 | $30.11F3 | −$370,359.15 | 233,625 | Direct | |
| Nov 10, 2026 | Common Stock | MOption exerciseAcquired | +20,000 | $6.88 | +$137,600 | 253,625 | Direct | |
| Nov 10, 2026 | Common Stock | SSaleDisposed | −12,800 | $30.32F4 | −$388,107.52 | 240,825 | Direct | |
| Nov 10, 2026 | Common Stock | SSaleDisposed | −7,200 | $30.97F5 | −$222,982.56 | 233,625 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 343,835 | Direct | |
| Nov 10, 2026 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 323,835 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.82 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.905 to $31.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.